Affimed Revenues up $AFMD $XHS
Affimed N.V., a clinical-stage bio pharmaceutical company, has announced its first quarter results for FY-2015. The results shows Revenues up from Euro 0.722 Million to Euro 2.538 Million, and EPS Loss of Euro -1.06 turned to EPS of 0.06 YoY. View the full earnings release here.
Affimed Revenues up $AFMD $XHS Read More »